Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702518 · ClinicalTrials.gov registry record · Phase 1
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02702518 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 58 participants.
The verdict
NCT02702518, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
Interventions
- DRUG Vehicle
- DRUG rhDNase I
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702518
The ClinicalTrials.gov registry entry for NCT02702518 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT02702518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702518 about?
NCT02702518 is a clinical study titled "rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease". The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
What is the current status of trial NCT02702518?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2016-04. Estimated completion is 2020-04-08.
What interventions are being tested in trial NCT02702518?
The interventions under investigation include: Vehicle (DRUG), rhDNase I (DRUG).
Who is sponsoring clinical trial NCT02702518?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.